Pioneering Regenerative Medicine
Without Immunosuppression
Pioneering Regenerative Medicine
Without Immunosuppression
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
Developing a Potential Cure for Type 1 Diabetes
Our lead program iTOL-102 combines our iTOL-100 technology with an inexhaustible supply of insulin producing allogeneic stem cell-derived pancreatic islets and is being developed as a potential cure for Type 1 Diabetes. In a pre-clinical non-human primate study, allogenic pancreatic islet cells co-implanted with SA-FasL microgel exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression.
Development Pipeline
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. Completes Pre-IND Meeting with U.S. FDA for Development Program as a Potential Cure for Type 1 Diabetes Without the Need for Life-long Immunosuppression
MIAMI, FL / March 1, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression, today announced it has...
iTolerance, Inc. Enters into Master Services Agreement with the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine to Advance iTOL-100 Platform Technology for Type 1 Diabetes
DRI to assist in advancing potential of iTOL-100 to enable engraftment and long-term survival of transplanted insulin producing stem cells without the use of chronic immunosuppressionPre-clinical studies conducted to date demonstrate iTOL-100 established durable,...
iTolerance, Inc. Announces Formation of Strategic Advisory Board and Appointment of Inaugural Members
Establishment of Strategic Advisory Board provides renowned business development, clinical and regulatory leadership and expertise as iTolerance advances its proprietary technologies enabling tissue, organoid or cell therapy without the need for life-long...